**Supplement (Online-only material)**

# Supplementary Table 1. Database Descriptions

| Database | Description | Claims Type | Update frequency | Data Lag,Time to 80% Completenessa | Enrollees Ages 5-17 yearsb | Count of IIS Jurisdictions Incorporated into Analysis |
| --- | --- | --- | --- | --- | --- | --- |
| CVS Health | CVS Health Clinical Trial Services (CVS CTS) transforms enrollment, demographic, and medical and drug claims data, for individuals enrolled from January 2018 forward in Aetna commercial including Affordable Care act (ACA) Marketplace, and Medicare Advantage health plans into a patient-centered, comprehensive Common Data Model (CDM).  | Fully Adjudicated | Monthly | ~ 3-4 months for IP claims, 2-3 months for OP claims, and 1-2 months for professional claims | 5-11 years: > 1.5 million12-15 years: > 991k16-17 years: > 558k | 14 |
| Optum Pre-adjudicated Claims | The Optum data includes enrollment, prescription drug and pre-adjudicated hospital and physician health insurance claims. The pre-adjudicated claims database includes claims for privately insured and Medicare Advantage enrollees. Hospital and physician claims undergo initial processing on a daily basis from a large number of providers across the US who accept patients with health insurance. | Pre-Adjudicated | Bi-Weekly | ~ 1-2 months for IP, OP, and professional claims | 5-11 years: > 1.3 million 12-15 years: > 840k16-17 years: > 429k | 18 |
| HealthCore | HealthCore, Inc. is a wholly-owned, research subsidiary of Elevance Health, Inc., a holding company owning several large US health plans associated with Anthem Blue Cross Blue Shield. HealthCore has a US population database including individually insured by commercial and Medicare Advantage plans, the HealthCore Integrated Research Environment (HIRE), with longitudinal data on health plan enrollees. | Fully Adjudicated | Monthly | ~ 2-3 months for IP claims and 1-2 months for OP and professional claims  | 5-11 years: > 1.8 million12-15 years: > 1.2 million16-17 years: > 647k | 0 |

*a Data lag based on 2020 claims delay distribution*

*b Average number of annual enrollees in a given age category between 2018-2020*

# Supplementary Table 2. Codes for COVID-19 Vaccine Administrations, Utilized in Claims and IIS data

| HCPCS/CPT Code | CVX Codes(IIS-Specific) | Manufacturer | Name | Age Group | Vaccine Administration Code | NDC 11 Labeler Product ID (Vial) | Dosing Interval |
| --- | --- | --- | --- | --- | --- | --- | --- |
| NA | NA | Pfizer | Pfizer-BioNTech COVID-19 Vaccine | 16+ years | NA | 00069-2025-0100069-2025-1000069-2025-25 | NA |
|
|
| 91308 | 219 | Pfizer | Pfizer-BioNTech COVID-19 Vaccine | 6 month - 5 years | 0081A (1st dose) | 59267-0078-0159267-0078-0259267-0078-04 | -21+ days between dose 1 and dose 2 |
| 0082A (second dose) |
| 91307 | 218 | Pfizer | Pfizer-BioNTech COVID-19 Pediatric Vaccine | 5-11 years | 0071A (1st dose) | 59267-1055-0159267-1055-0259267-1055-04 | -21+ days between dose 1 and dose 2-For immunocompromised, 21+ days between dose 1 and dose 2, and 28+ days between dose 2 and additional primary dose (dose 3)  |
| 0072A (2nd dose) |
| 0073A (3rd dose) |
| 0074A (booster dose) |
| 91305 | 217 | Pfizer | Pfizer-BioNTech COVID-19 Vaccine | 12+ years | 0051A (1st dose) | 59267-1025-0159267-1025-0259267-1025-0359267-1025-04 | -21+ days between dose 1 and dose 2 and 5+ months between dose 2 and third/booster dose- For immunocompromised, 21+ days between dose 1 and dose 2, 28+ days between dose 2 and dose 3. Additionally, booster dose recommended 3+ months after primary series  |
| 0052A (2nd dose) |
| 0053A (3rd dose) |
| 0054A (booster dose) |
| 91300 | 208 | Pfizer | Pfizer-BioNTech COVID-19 Vaccine | 12+ years | 0001A (1st dose) | 59267-1000-0159267-1000-0259267-1000-03 | -21+ days between dose 1 and dose 2 and 5+ months between dose 2 and third/booster dose- For immunocompromised, 21+ days between dose 1 and dose 2, 28+ days between dose 2 and dose 3. Additionally, booster dose recommended 3+ months after primary series  |
| 0002A (2nd dose) |
| 0003A (3rd dose) |
| 0004A (booster dose) |

**Supplementary** **Table 3. Outcomes, Age Groups, Settings, Clean Windows, Risk Windows, and Analysis Type for the Pediatric Population**

| **Outcome** | **Age Group of Interest** | **Setting** | **Clean Window** | **Risk Window** | **Analysis Type** |
| --- | --- | --- | --- | --- | --- |
| **Pediatric Outcomes** |
| Myocarditis/Pericarditis | Ages 5-17 years | IP, OP/PB | 365 days | 1-7 days[1] | Descriptive and Sequential Testing |
| Ages 5-17 years | IP, OP/PB | 365 days | 1-21 days[2] | Descriptive and Sequential Testing |
| Ages 5-17 years | IP, OP-ED | 365 days | 1-7 days[1] | Descriptive and Sequential Testing |
| Ages 5-17 years | IP, OP-ED | 365 days | 1-21 days[2] | Descriptive and Sequential Testing |
| Guillain-Barré syndrome (GBS) | Ages 5-17 years | IP- primary position only | 365 days | 1-42 days[3,4] | Descriptive Only |
| Multisystem inflammatory syndrome in children (MIS-C) | Ages 5-17 years | IP, OP-ED | 365 days | 1-42 days[5] | Descriptive Only |
| Encephalitis / myelitis / encephalomyelitis | Ages 5-17 years | IP | 183 days | 1-42 days[6] | Descriptive and Sequential Testing |
| Transverse myelitis | Ages 5-17 years | IP, OP-ED | 365 days | 1-42 days[7] | Descriptive Only |
| Anaphylaxis | Ages 5-17 years | IP, OP-ED | 30 days | 0-1 day[8,9] | Descriptive and Sequential Testing |
| Common thromboses with thrombocytopenia | Ages 5-17 years | [Definition below]\*\* | 365 days | 1-28 days[10] | Descriptive and Sequential Testing |
| Unusual site thrombosis (broad)with thrombocytopenia- cerebral and abdominal thrombosis | Ages 5-17 years | [Definition below]\*\* | 365 days | 1-28 days[11] | Descriptive Only |
| Seizures/Convulsions | Ages 5-17 years | IP, OP-ED | 42 days | 0-7 days[12] | Descriptive and Sequential Testing |
| Bell’s palsy | Ages 5-17 years | IP, OP/PB | 183 days | 1-42 days[13] | Descriptive and Sequential Testing |
| Deep vein thrombosis (DVT) | Ages 5-17 years | IP, OP/PB | 365 days | 1-28 days[14-16] | Descriptive and Sequential Testing |
| Pulmonary embolism (PE) | Ages 5-17 years | IP, OP/PB | 365 days | 1-28 days[14-16] | Descriptive and Sequential Testing |
| Disseminated intravascular coagulation (DIC) | Ages 5-17 years | IP, OP-ED | 365 days | 1-28 days[17] | Descriptive and Sequential Testing |
| Immune thrombocytopenia (ITP) | Ages 5-17 years | IP, OP/PB | 365 days | 1-42 days[18,19] | Descriptive and Sequential Testing |
| Kawasaki disease | Ages 5-17 years | IP, OP/PB | 365 days | 1-28 days[20,21] | Descriptive Only |
| Narcolepsy | Ages 5-17 years | IP, OP/PB | 365 days | 1-42 days[22-24] | Descriptive and Sequential Testing |
| Appendicitis | Ages 5-17 years | IP, OP-ED | 365 days | 1-42 days[25,26] | Descriptive and Sequential Testing |
| Non-hemorrhagic stroke | Ages 5-17 years | IP | 365 days | 1-28 days[27,28] | Descriptive and Sequential Testing |
| Hemorrhagic stroke | Ages 5-17 years | IP | 365 days | 1-28 days[27,28] | Descriptive Only |
| Acute myocardial infarction | Ages 5-17 years | IP | 365 days | 1-28 days[27,28] | Descriptive Only |

*Definitions: Clean Window is defined as an interval used to define incident outcomes where an individual enters the study cohort only if the outcome of interest did not occur during that interval. Risk Window is defined as an interval during which occurrence of the outcome of interest will be included in the analyses.*

*Setting Definitions: IP refers to inpatient facility claims. OP-ED refers to a subset of outpatient facility claims occurring in the emergency department. OP/PB refers to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service. For myocarditis/pericarditis, analyses were performed using two different risk windows (1-7 days; 1-21 days) and two different care settings (inpatient, outpatient and provider services; inpatient and outpatient-emergency department) based on clinician input and available literature*

*\*All outcomes were identified using ICD-10-CM Diagnosis codes.29,30 The classification of outcomes into those to be monitored descriptively and those monitored via sequential testing is based on the availability of estimable background rates for the outcomes and the expected frequency of events*

*\*\* Both Common thromboses with thrombocytopenia and Unusual site thrombosis (broad) with thrombocytopenia are combined outcomes consisting of a thrombotic event (made up of other events such as acute myocardial infarction, deep vein thrombosis etc.,) and a thrombocytopenia event (defined in the IP, OP/PB setting). The overall setting definition for each outcome depends on individual setting definitions for each of these components*

# Supplementary Table 4. Sequential Testing Results in Health Plan Members Aged 5-17 years by Outcome Following BNT162b2 All Doses (Primary Series, Dose 1, Dose 2, and Third/Booster Dose) in CVS Health, HealthCore, and Optum Databases

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcome** | **Dose** | **Age Group** | **CVS** | **HealthCore** | **Optum** |
| **# of Doses** | **Outcomes** | **Person-Time (Days)** | **RR** | **# of Doses** | **Outcomes** | **Person-Time (Days)** | **RR** | **# of Doses** | **Outcomes** | **Person-Time (Days)** | **RR** |
| Anaphylaxis | Primary Series | 5-11 | 739,974 | <11 | 1,478,203 | 3.50 | 727,202 | <11 | 1,449,597 | 5.39 | 680,186 | 0 | 1,348,722 | 0.00 |
| 12-15 | 689,683 | <11 | 1,378,721 | 3.95 | 772,261 | <11 | 1,542,848 | 0.87 | 669,816 | <11 | 1,337,763 | 5.50 |
| 16-17 | 349,440 | <11 | 698,487 | 4.78 | 393,066 | <11 | 785,267 | 1.48 | 337,391 | <11 | 673,972 | 3.95 |
| Dose 1 | 5-11 | 391,692 | <11 | 782,495 | 3.30 | 404,716 | <11 | 807,094 | 4.81 | 371,307 | 0 | 735,473 | 0.00 |
| 12-15 | 365,895 | <11 | 731,399 | 2.48 | 425,137 | <11 | 849,202 | 1.58 | 360,549 | <11 | 719,866 | 7.67 |
| 16-17 | 187,361 | <11 | 374,491 | 8.92 | 221,794 | <11 | 443,014 | 2.63 | 185,157 | <11 | 369,815 | 7.20 |
| Dose 2 | 5-11 | 348,282 | <11 | 695,708 | 3.73 | 322,486 | <11 | 642,503 | 6.14 | 308,879 | 0 | 613,249 | 0.00 |
| 12-15 | 323,788 | <11 | 647,322 | 5.61 | 347,124 | 0 | 693,646 | 0.00 | 309,267 | <11 | 617,897 | 2.98 |
| 16-17 | 162,079 | 0 | 323,996 | 0.00 | 171,272 | 0 | 342,253 | 0.00 | 152,234 | 0 | 304,157 | 0.00 |
| Dose 3 | 5-11 | 13,611 | 0 | 23,369 | 0.00 | 1,481 | 0 | 2,929 | 0.00 | 21,450 | 0 | 32,023 | 0.00 |
| 12-15 | 96,975 | <11 | 192,972 | 10.17 | 66,312 | <11 | 131,608 | 11.11 | 86,087 | 0 | 170,125 | 0.00 |
| 16-17 | 66,162 | 0 | 131,909 | 0.00 | 45,560 | 0 | 90,677 | 0.00 | 55,445 | <11 | 110,204 | 12.24 |
| Appendicitis | Primary Series | 5-11 | 602,964 | 65 | 19,346,774 | 1.13 | 604,588 | 45 | 19,727,071 | 0.74 | 572,135 | 48 | 18,187,457 | 0.70 |
| 12-15 | 572,563 | 90 | 18,568,541 | 1.10 | 652,741 | 88 | 21,526,254 | 0.87 | 565,049 | 87 | 18,251,418 | 0.94 |
| 16-17 | 291,301 | 44 | 9,505,378 | 0.99 | 334,608 | 55 | 11,200,565 | 1.01 | 285,726 | 47 | 9,336,794 | 0.89 |
| Dose 1 | 5-11 | 318,219 | 27 | 7,902,725 | 1.13 | 335,279 | 21 | 8,916,128 | 0.74 | 310,350 | 25 | 7,865,129 | 0.84 |
| 12-15 | 301,730 | 29 | 7,378,691 | 0.89 | 356,294 | 42 | 9,243,397 | 0.97 | 302,196 | 41 | 7,529,320 | 1.07 |
| 16-17 | 155,214 | 20 | 3,875,060 | 1.10 | 186,911 | 27 | 5,072,915 | 1.10 | 155,615 | 17 | 4,028,348 | 0.75 |
| Dose 2 | 5-11 | 284,745 | 38 | 11,444,049 | 1.12 | 269,309 | 24 | 10,810,943 | 0.73 | 261,785 | 24 | 10,322,328 | 0.62 |
| 12-15 | 270,833 | 61 | 11,189,850 | 1.24 | 296,447 | 46 | 12,282,857 | 0.80 | 262,853 | 47 | 10,722,098 | 0.86 |
| 16-17 | 136,087 | 24 | 5,630,318 | 0.91 | 147,697 | 28 | 6,127,650 | 0.93 | 130,111 | 30 | 5,308,446 | 1.00 |
| Dose 3 | 5-11 | 11,438 | 0 | 124,510 | 0.00 | 1,339 | 0 | 45,888 | 0.00 | 19,033 | 0 | 369,675 | 0.00 |
| 12-15 | 86,036 | 11 | 3,355,000 | 0.83 | 63,891 | <11 | 2,482,199 | 0.74 | 79,497 | <11 | 3,073,489 | 0.55 |
| 16-17 | 57,772 | <11 | 2,289,307 | 0.81 | 43,066 | <11 | 1,697,120 | 0.83 | 50,525 | 15 | 1,951,045 | 1.43 |
| Bell's palsy | Primary Series | 5-11 | 675,779 | 13 | 21,785,514 | 1.17 | 673,161 | 12 | 22,150,403 | 1.01 | 635,935 | <11 | 20,175,890 | 0.53 |
| 12-15 | 623,855 | 14 | 20,275,128 | 1.08 | 709,401 | 22 | 23,491,552 | 1.18 | 615,692 | 11 | 19,893,989 | 0.57 |
| 16-17 | 314,933 | <11 | 10,298,281 | 0.74 | 360,346 | <11 | 12,108,973 | 0.78 | 308,945 | <11 | 10,096,665 | 0.84 |
| Dose 1 | 5-11 | 357,777 | <11 | 8,944,746 | 0.87 | 374,144 | <11 | 10,005,282 | 1.28 | 345,766 | <11 | 8,760,032 | 0.24 |
| 12-15 | 328,898 | <11 | 8,079,623 | 0.97 | 386,972 | <11 | 10,101,801 | 1.01 | 329,457 | <11 | 8,231,955 | 0.50 |
| 16-17 | 167,972 | <11 | 4,216,467 | 0.61 | 201,636 | <11 | 5,513,254 | 0.38 | 168,583 | <11 | 4,378,145 | 1.11 |
| Dose 2 | 5-11 | 318,002 | <11 | 12,840,768 | 1.38 | 299,017 | <11 | 12,145,121 | 0.78 | 290,169 | <11 | 11,415,858 | 0.75 |
| 12-15 | 294,957 | <11 | 12,195,505 | 1.28 | 322,429 | <11 | 13,389,751 | 1.32 | 286,235 | <11 | 11,662,034 | 0.62 |
| 16-17 | 146,961 | <11 | 6,081,814 | 1.05 | 158,710 | <11 | 6,595,719 | 1.11 | 140,362 | <11 | 5,718,520 | 0.64 |
| Dose 3 | 5-11 | 12,471 | 0 | 164,697 | 0.00 | 1,441 | 0 | 50,751 | 0.00 | 20,761 | 0 | 409,823 | 0.00 |
| 12-15 | 91,094 | <11 | 3,623,831 | 0.93 | 66,062 | <11 | 2,656,746 | 1.10 | 83,933 | <11 | 3,243,633 | 1.66 |
| 16-17 | 62,499 | <11 | 2,503,089 | 1.08 | 45,412 | <11 | 1,825,062 | 0.63 | 54,106 | <11 | 2,086,728 | 0.60 |
| Common thromboses with thrombocytopenia | Primary Series | 5-11 | 603,631 | 0 | 15,063,681 | 0.00 | 605,189 | 0 | 15,253,024 | 0.00 | 572,768 | 0 | 14,156,025 | 0.00 |
| 12-15 | 573,509 | 0 | 14,326,988 | 0.00 | 653,821 | <11 | 16,493,102 | 1.51 | 566,008 | 0 | 14,069,963 | 0.00 |
| 16-17 | 291,770 | <11 | 7,309,572 | 3.28 | 335,214 | 0 | 8,514,719 | 0.00 | 286,191 | 0 | 7,151,741 | 0.00 |
| Dose 1 | 5-11 | 318,571 | 0 | 7,281,081 | 0.00 | 335,610 | 0 | 7,872,732 | 0.00 | 310,689 | 0 | 7,096,078 | 0.00 |
| 12-15 | 302,226 | 0 | 6,810,180 | 0.00 | 356,881 | 0 | 8,241,243 | 0.00 | 302,702 | 0 | 6,848,840 | 0.00 |
| 16-17 | 155,466 | <11 | 3,530,834 | 3.40 | 187,251 | 0 | 4,401,614 | 0.00 | 155,870 | 0 | 3,578,004 | 0.00 |
| Dose 2 | 5-11 | 285,060 | 0 | 7,782,600 | 0.00 | 269,579 | 0 | 7,380,292 | 0.00 | 262,079 | 0 | 7,059,947 | 0.00 |
| 12-15 | 271,283 | 0 | 7,516,808 | 0.00 | 296,940 | <11 | 8,251,859 | 3.02 | 263,306 | 0 | 7,221,123 | 0.00 |
| 16-17 | 136,304 | <11 | 3,778,738 | 3.17 | 147,963 | 0 | 4,113,105 | 0.00 | 130,321 | 0 | 3,573,737 | 0.00 |
| Dose 3 | 5-11 | 11,446 | 0 | 89,279 | 0.00 | 1,341 | 0 | 33,982 | 0.00 | 19,048 | 0 | 291,412 | 0.00 |
| 12-15 | 86,169 | 0 | 2,293,118 | 0.00 | 63,983 | 0 | 1,724,614 | 0.00 | 79,622 | 0 | 2,092,120 | 0.00 |
| 16-17 | 57,851 | 0 | 1,553,697 | 0.00 | 43,144 | 0 | 1,163,968 | 0.00 | 50,629 | 0 | 1,327,042 | 0.00 |
| Deep vein thrombosis (DVT) | Primary Series | 5-11 | 603,606 | 0 | 15,062,839 | 0.00 | 605,162 | 0 | 15,252,307 | 0.00 | 572,759 | 0 | 14,155,801 | 0.00 |
| 12-15 | 573,474 | <11 | 14,325,938 | 0.24 | 653,791 | <11 | 16,492,356 | 1.19 | 565,957 | 0 | 14,068,697 | 0.00 |
| 16-17 | 291,691 | <11 | 7,307,399 | 0.30 | 335,152 | <11 | 8,513,141 | 1.14 | 286,133 | <11 | 7,150,307 | 0.34 |
| Dose 1 | 5-11 | 318,556 | 0 | 7,280,652 | 0.00 | 335,593 | 0 | 7,872,323 | 0.00 | 310,683 | 0 | 7,095,938 | 0.00 |
| 12-15 | 302,208 | 0 | 6,809,690 | 0.00 | 356,865 | <11 | 8,240,878 | 1.43 | 302,674 | 0 | 6,848,207 | 0.00 |
| 16-17 | 155,423 | 0 | 3,529,742 | 0.00 | 187,219 | <11 | 4,400,848 | 1.77 | 155,836 | <11 | 3,577,199 | 0.34 |
| Dose 2 | 5-11 | 285,050 | 0 | 7,782,187 | 0.00 | 269,569 | 0 | 7,379,984 | 0.00 | 262,076 | 0 | 7,059,863 | 0.00 |
| 12-15 | 271,266 | <11 | 7,516,248 | 0.45 | 296,926 | <11 | 8,251,478 | 0.95 | 263,283 | 0 | 7,220,490 | 0.00 |
| 16-17 | 136,268 | <11 | 3,777,657 | 0.58 | 147,933 | <11 | 4,112,293 | 0.47 | 130,297 | <11 | 3,573,108 | 0.34 |
| Dose 3 | 5-11 | 11,446 | 0 | 89,251 | 0.00 | 1,339 | 0 | 33,926 | 0.00 | 19,046 | 0 | 291,366 | 0.00 |
| 12-15 | 86,161 | 0 | 2,292,866 | 0.00 | 63,976 | 0 | 1,724,418 | 0.00 | 79,614 | <11 | 2,091,896 | 1.69 |
| 16-17 | 57,840 | 0 | 1,553,387 | 0.00 | 43,134 | 0 | 1,163,714 | 0.00 | 50,621 | 0 | 1,326,846 | 0.00 |
| Disseminated intravascular coagulation (DIC) | Primary Series | 5-11 | 603,622 | 0 | 14,973,673 | 0.00 | 605,194 | <11 | 15,099,403 | 4.09 | 572,773 | 0 | 14,102,730 | 0.00 |
| 12-15 | 573,509 | 0 | 14,304,512 | 0.00 | 653,820 | 0 | 16,440,576 | 0.00 | 566,010 | 0 | 14,053,504 | 0.00 |
| 16-17 | 291,775 | 0 | 7,298,174 | 0.00 | 335,215 | 0 | 8,488,263 | 0.00 | 286,198 | 0 | 7,144,258 | 0.00 |
| Dose 1 | 5-11 | 318,566 | 0 | 7,238,894 | 0.00 | 335,613 | 0 | 7,813,485 | 0.00 | 310,692 | 0 | 7,067,211 | 0.00 |
| 12-15 | 302,226 | 0 | 6,798,069 | 0.00 | 356,881 | 0 | 8,212,755 | 0.00 | 302,703 | 0 | 6,838,690 | 0.00 |
| 16-17 | 155,469 | 0 | 3,524,012 | 0.00 | 187,252 | 0 | 4,385,669 | 0.00 | 155,874 | 0 | 3,573,645 | 0.00 |
| Dose 2 | 5-11 | 285,056 | 0 | 7,734,779 | 0.00 | 269,581 | <11 | 7,285,918 | 8.81 | 262,081 | 0 | 7,035,519 | 0.00 |
| 12-15 | 271,283 | 0 | 7,506,443 | 0.00 | 296,939 | 0 | 8,227,821 | 0.00 | 263,307 | 0 | 7,214,814 | 0.00 |
| 16-17 | 136,306 | 0 | 3,774,162 | 0.00 | 147,963 | 0 | 4,102,594 | 0.00 | 130,324 | 0 | 3,570,613 | 0.00 |
| Dose 3 | 5-11 | 11,444 | 0 | 87,578 | 0.00 | 1,341 | 0 | 32,828 | 0.00 | 19,048 | 0 | 230,388 | 0.00 |
| 12-15 | 86,170 | 0 | 2,248,385 | 0.00 | 63,982 | 0 | 1,665,851 | 0.00 | 79,622 | <11 | 2,062,986 | 10.82 |
| 16-17 | 57,854 | 0 | 1,536,756 | 0.00 | 43,144 | 0 | 1,139,733 | 0.00 | 50,630 | 0 | 1,317,447 | 0.00 |
| Encephalitis / myelitis / encephalomyelitis | Primary Series | 5-11 | 675,862 | <11 | 21,498,513 | 0.83 | 673,262 | 0 | 21,766,827 | 0.00 | 636,003 | 0 | 20,177,981 | 0.00 |
| 12-15 | 623,934 | <11 | 20,201,159 | 1.65 | 709,494 | <11 | 23,353,158 | 1.14 | 615,778 | <11 | 19,896,658 | 0.62 |
| 16-17 | 315,002 | <11 | 10,263,177 | 1.29 | 360,397 | 0 | 12,041,649 | 0.00 | 308,985 | 0 | 10,097,982 | 0.00 |
| Dose 1 | 5-11 | 357,821 | 0 | 8,833,757 | 0.00 | 374,206 | 0 | 9,883,921 | 0.00 | 345,807 | 0 | 8,761,121 | 0.00 |
| 12-15 | 328,944 | 0 | 8,041,758 | 0.00 | 387,018 | 0 | 10,027,824 | 0.00 | 329,507 | <11 | 8,233,208 | 1.50 |
| 16-17 | 168,011 | 0 | 4,196,563 | 0.00 | 201,662 | 0 | 5,473,212 | 0.00 | 168,607 | 0 | 4,378,790 | 0.00 |
| Dose 2 | 5-11 | 318,041 | <11 | 12,664,756 | 1.44 | 299,056 | 0 | 11,882,906 | 0.00 | 290,196 | 0 | 11,416,860 | 0.00 |
| 12-15 | 294,990 | <11 | 12,159,401 | 2.75 | 322,476 | <11 | 13,325,334 | 1.99 | 286,271 | 0 | 11,663,450 | 0.00 |
| 16-17 | 146,991 | <11 | 6,066,614 | 2.18 | 158,735 | 0 | 6,568,437 | 0.00 | 140,378 | 0 | 5,719,192 | 0.00 |
| Dose 3 | 5-11 | 12,473 | 0 | 134,559 | 0.00 | 1,441 | 0 | 47,953 | 0.00 | 20,764 | 0 | 409,895 | 0.00 |
| 12-15 | 91,108 | 0 | 3,473,475 | 0.00 | 66,067 | 0 | 2,508,168 | 0.00 | 83,940 | 0 | 3,243,927 | 0.00 |
| 16-17 | 62,513 | 0 | 2,441,902 | 0.00 | 45,421 | 0 | 1,765,174 | 0.00 | 54,118 | 0 | 2,087,194 | 0.00 |
| Immune thrombocytopenia (ITP) | Primary Series | 5-11 | 603,512 | <11 | 19,489,519 | 2.09 | 605,104 | <11 | 19,960,730 | 1.91 | 572,717 | <11 | 18,205,909 | 1.49 |
| 12-15 | 573,435 | <11 | 18,629,280 | 1.08 | 653,693 | 12 | 21,635,214 | 2.53 | 565,907 | <11 | 18,279,130 | 0.85 |
| 16-17 | 291,710 | <11 | 9,535,013 | 1.00 | 335,123 | <11 | 11,256,120 | 1.78 | 286,147 | <11 | 9,350,455 | 0.60 |
| Dose 1 | 5-11 | 318,509 | <11 | 7,961,202 | 2.04 | 335,563 | <11 | 8,994,830 | 2.38 | 310,663 | <11 | 7,872,969 | 0.57 |
| 12-15 | 302,187 | <11 | 7,406,353 | 1.09 | 356,812 | <11 | 9,297,471 | 1.96 | 302,645 | <11 | 7,540,525 | 0.41 |
| 16-17 | 155,435 | <11 | 3,889,573 | 0.82 | 187,203 | <11 | 5,103,168 | 3.29 | 155,845 | <11 | 4,034,298 | 0.46 |
| Dose 2 | 5-11 | 285,003 | <11 | 11,528,317 | 2.13 | 269,541 | <11 | 10,965,900 | 1.51 | 262,054 | <11 | 10,332,940 | 2.20 |
| 12-15 | 271,248 | <11 | 11,222,927 | 1.07 | 296,881 | <11 | 12,337,743 | 2.95 | 263,262 | <11 | 10,738,605 | 1.16 |
| 16-17 | 136,275 | <11 | 5,645,440 | 1.12 | 147,920 | <11 | 6,152,952 | 0.54 | 130,302 | <11 | 5,316,157 | 0.70 |
| Dose 3 | 5-11 | 11,441 | 0 | 150,770 | 0.00 | 1,340 | 0 | 47,511 | 0.00 | 19,043 | 0 | 369,817 | 0.00 |
| 12-15 | 86,150 | 0 | 3,430,922 | 0.00 | 63,971 | 0 | 2,573,226 | 0.00 | 79,614 | 0 | 3,078,046 | 0.00 |
| 16-17 | 57,838 | <11 | 2,320,008 | 1.43 | 43,127 | <11 | 1,735,767 | 2.09 | 50,620 | <11 | 1,954,814 | 1.94 |
| Myocarditis/Pericarditis (1-21 day risk window, all settings) | Primary Series | 5-11 | 603,585 | <11 | 12,485,896 | 3.44 | 605,143 | <11 | 12,561,157 | 3.03 | 572,742 | <11 | 11,698,334 | 4.35 |
| 12-15 | 573,445 | 31 | 11,941,308 | **10.62\*** | 653,742 | 23 | 13,640,542 | **9.06\*** | 565,967 | 35 | 11,700,690 | **10.19\*** |
| 16-17 | 291,721 | 28 | 6,071,623 | **12.65\*** | 335,160 | 23 | 6,990,316 | **7.44\*** | 286,151 | 13 | 5,912,687 | **3.47\*** |
| Dose 1 | 5-11 | 318,545 | <11 | 6,590,589 | 3.25 | 335,584 | <11 | 6,969,330 | 1.80 | 310,676 | <11 | 6,341,416 | 3.20 |
| 12-15 | 302,195 | <11 | 6,282,142 | 2.60 | 356,836 | <11 | 7,433,347 | 2.89 | 302,684 | <11 | 6,254,311 | **4.90\*** |
| 16-17 | 155,443 | <11 | 3,228,595 | **5.10\*** | 187,217 | <11 | 3,897,594 | 4.07 | 155,846 | <11 | 3,217,800 | 0.98 |
| Dose 2 | 5-11 | 285,040 | <11 | 5,895,307 | 3.67 | 269,559 | <11 | 5,591,827 | 4.59 | 262,066 | <11 | 5,356,918 | 5.72 |
| 12-15 | 271,250 | <11 | 5,659,166 | **19.53\*** | 296,906 | <11 | 6,207,195 | **16.45\*** | 263,283 | <11 | 5,446,379 | **16.26\*** |
| 16-17 | 136,278 | <11 | 2,843,028 | **21.21\*** | 147,943 | <11 | 3,092,722 | **11.68\*** | 130,305 | <11 | 2,694,887 | **6.45\*** |
| Dose 3 | 5-11 | 11,443 | 0 | 94,226 | 0.00 | 1,341 | 0 | 27,092 | 0.00 | 19,047 | 0 | 249,882 | 0.00 |
| 12-15 | 86,157 | <11 | 1,753,863 | 2.52 | 63,977 | <11 | 1,320,089 | 14.01 | 79,609 | <11 | 1,588,091 | 4.47 |
| 16-17 | 57,844 | <11 | 1,180,160 | **9.93\*** | 43,134 | <11 | 885,705 | 5.63 | 50,621 | <11 | 1,007,613 | 4.90 |
| Myocarditis/Pericarditis (1-7 day risk window, all settings) | Primary Series | 5-11 | 603,585 | <11 | 4,201,903 | 5.10 | 605,143 | <11 | 4,218,557 | 8.94 | 572,742 | <11 | 3,965,884 | 10.26 |
| 12-15 | 573,445 | 22 | 4,005,827 | **22.44\*** | 653,742 | 14 | 4,569,263 | **16.43\*** | 565,967 | 26 | 3,943,897 | **22.44\*** |
| 16-17 | 291,721 | 22 | 2,037,440 | **29.60\*** | 335,160 | 19 | 2,341,915 | **18.31\*** | 286,151 | 11 | 1,993,951 | **8.72\*** |
| Dose 1 | 5-11 | 318,545 | <11 | 2,218,337 | 4.81 | 335,584 | <11 | 2,340,724 | 5.33 | 310,676 | <11 | 2,150,922 | 4.72 |
| 12-15 | 302,195 | <11 | 2,110,944 | 1.93 | 356,836 | 0 | 2,494,047 | 0.00 | 302,684 | <11 | 2,109,334 | 6.45 |
| 16-17 | 155,443 | <11 | 1,085,398 | 7.58 | 187,217 | <11 | 1,307,806 | 6.91 | 155,846 | <11 | 1,085,979 | 2.91 |
| Dose 2 | 5-11 | 285,040 | <11 | 1,983,566 | 5.43 | 269,559 | <11 | 1,877,833 | 13.54 | 262,066 | <11 | 1,814,962 | 16.85 |
| 12-15 | 271,250 | <11 | 1,894,883 | **45.33\*** | 296,906 | 14 | 2,075,216 | **36.17\*** | 263,283 | <11 | 1,834,563 | **40.83\*** |
| 16-17 | 136,278 | <11 | 952,042 | **54.68\*** | 147,943 | <11 | 1,034,109 | **32.71\*** | 130,305 | <11 | 907,972 | **15.66\*** |
| Dose 3 | 5-11 | 11,443 | 0 | 48,031 | 0.00 | 1,341 | 0 | 9,287 | 0.00 | 19,047 | 0 | 107,282 | 0.00 |
| 12-15 | 86,157 | <11 | 594,686 | 7.41 | 63,977 | <11 | 445,495 | **40.59\*** | 79,609 | <11 | 544,542 | 13.05 |
| 16-17 | 57,844 | <11 | 400,044 | **29.22\*** | 43,134 | <11 | 299,708 | 8.20 | 50,621 | <11 | 347,047 | 14.22 |
| Myocarditis/Pericarditis (1-21 day risk window, IP, OP-ED) | Primary Series | 5-11 | 603,627 | 0 | 12,415,336 | 0.00 | 605,187 | <11 | 12,519,919 | 16.62 | 572,773 | <11 | 11,698,984 | 3.49 |
| 12-15 | 573,501 | 19 | 11,924,350 | **22.98\*** | 653,800 | 12 | 13,627,693 | **16.86\*** | 566,007 | 21 | 11,701,527 | **18.64\*** |
| 16-17 | 291,767 | 22 | 6,063,130 | **20.76\*** | 335,210 | 15 | 6,983,839 | **9.07\*** | 286,174 | <11 | 5,913,153 | **4.98\*** |
| Dose 1 | 5-11 | 318,568 | 0 | 6,554,190 | 0.00 | 335,609 | <11 | 6,950,073 | 14.71 | 310,693 | 0 | 6,341,772 | 0.00 |
| 12-15 | 302,223 | 0 | 6,272,569 | 0.00 | 356,870 | 0 | 7,425,502 | 0.00 | 302,703 | <11 | 6,254,710 | 4.98 |
| 16-17 | 155,466 | <11 | 3,223,290 | **8.87\*** | 187,249 | <11 | 3,893,432 | 4.35 | 155,858 | <11 | 3,218,052 | 2.61 |
| Dose 2 | 5-11 | 285,059 | 0 | 5,861,146 | 0.00 | 269,578 | <11 | 5,569,846 | 19.10 | 262,080 | <11 | 5,357,212 | 7.62 |
| 12-15 | 271,278 | 19 | 5,651,781 | **48.61\*** | 296,930 | 12 | 6,202,191 | **37.07\*** | 263,304 | <11 | 5,446,817 | **34.34\*** |
| 16-17 | 136,301 | <11 | 2,839,840 | **34.24\*** | 147,961 | <11 | 3,090,407 | **15.01\*** | 130,316 | <11 | 2,695,101 | **7.81\*** |
| Dose 3 | 5-11 | 11,446 | 0 | 68,786 | 0.00 | 1,341 | 0 | 26,861 | 0.00 | 19,048 | 0 | 249,884 | 0.00 |
| 12-15 | 86,167 | <11 | 1,714,547 | 9.72 | 63,982 | <11 | 1,305,505 | 35.96 | 79,616 | 0 | 1,588,218 | 0.00 |
| 16-17 | 57,854 | <11 | 1,166,224 | 16.47 | 43,143 | <11 | 879,636 | 10.98 | 50,629 | <11 | 1,007,781 | 4.33 |
| Myocarditis/Pericarditis (1-7 day risk window, IP, OP-ED) | Primary Series | 5-11 | 603,627 | 0 | 4,176,754 | 0.00 | 605,187 | <11 | 4,207,157 | 48.87 | 572,773 | <11 | 3,966,101 | 10.29 |
| 12-15 | 573,501 | 19 | 3,999,983 | **68.36\*** | 653,800 | <11 | 4,565,641 | **41.78\*** | 566,007 | 19 | 3,944,177 | **50.01\*** |
| 16-17 | 291,767 | 18 | 2,034,590 | **50.55\*** | 335,210 | 13 | 2,340,241 | **23.39\*** | 286,174 | <11 | 1,994,109 | **14.77\*** |
| Dose 1 | 5-11 | 318,568 | 0 | 2,205,071 | 0.00 | 335,609 | <11 | 2,335,146 | 43.40 | 310,693 | 0 | 2,151,041 | 0.00 |
| 12-15 | 302,223 | 0 | 2,107,581 | 0.00 | 356,870 | 0 | 2,491,770 | 0.00 | 302,703 | <11 | 2,109,467 | 9.84 |
| 16-17 | 155,466 | <11 | 1,083,649 | 15.82 | 187,249 | <11 | 1,306,721 | 6.45 | 155,858 | <11 | 1,086,063 | 7.75 |
| Dose 2 | 5-11 | 285,059 | 0 | 1,971,683 | 0.00 | 269,578 | <11 | 1,872,011 | 55.92 | 262,080 | <11 | 1,815,060 | 22.49 |
| 12-15 | 271,278 | 19 | 1,892,402 | **144.90\*** | 296,930 | <11 | 2,073,871 | **92.06\*** | 263,304 | <11 | 1,834,710 | **96.22\*** |
| 16-17 | 136,301 | <11 | 950,941 | **90.11\*** | 147,961 | <11 | 1,033,520 | **44.75\*** | 130,316 | <11 | 908,046 | **23.17\*** |
| Dose 3 | 5-11 | 11,446 | 0 | 23,687 | 0.00 | 1,341 | 0 | 9,233 | 0.00 | 19,048 | 0 | 107,284 | 0.00 |
| 12-15 | 86,167 | <11 | 579,688 | 28.38 | 63,982 | <11 | 441,307 | 102.61 | 79,616 | 0 | 544,585 | 0.00 |
| 16-17 | 57,854 | <11 | 394,604 | **48.16\*** | 43,143 | <11 | 297,977 | 31.73 | 50,629 | <11 | 347,103 | 12.56 |
| Narcolepsy | Primary Series | 5-11 | 603,613 | <11 | 19,492,848 | 3.00 | 605,180 | <11 | 19,963,122 | 0.47 | 572,762 | 0 | 18,207,458 | 0.00 |
| 12-15 | 573,450 | <11 | 18,629,851 | 0.50 | 653,703 | <11 | 21,635,586 | 0.73 | 565,952 | <11 | 18,280,657 | 0.76 |
| 16-17 | 291,655 | <11 | 9,533,109 | 0.82 | 335,066 | <11 | 11,254,465 | 0.76 | 286,088 | <11 | 9,348,810 | 0.60 |
| Dose 1 | 5-11 | 318,562 | <11 | 7,962,580 | 1.82 | 335,604 | <11 | 8,995,962 | 1.02 | 310,686 | 0 | 7,873,597 | 0.00 |
| 12-15 | 302,195 | <11 | 7,406,603 | 0.94 | 356,822 | <11 | 9,297,814 | 1.41 | 302,671 | <11 | 7,541,252 | 0.31 |
| 16-17 | 155,400 | <11 | 3,888,553 | 0.67 | 187,163 | <11 | 5,102,168 | 0.48 | 155,815 | <11 | 4,033,705 | 0.46 |
| Dose 2 | 5-11 | 285,051 | <11 | 11,530,268 | 3.82 | 269,576 | 0 | 10,967,160 | 0.00 | 262,076 | 0 | 10,333,861 | 0.00 |
| 12-15 | 271,255 | <11 | 11,223,248 | 0.21 | 296,881 | <11 | 12,337,772 | 0.21 | 263,281 | <11 | 10,739,405 | 1.08 |
| 16-17 | 136,255 | <11 | 5,644,556 | 1.15 | 147,903 | <11 | 6,152,297 | 0.99 | 130,273 | <11 | 5,315,105 | 0.70 |
| Dose 3 | 5-11 | 11,446 | 0 | 150,873 | 0.00 | 1,341 | 0 | 47,553 | 0.00 | 19,046 | 0 | 369,915 | 0.00 |
| 12-15 | 86,162 | <11 | 3,431,411 | 1.46 | 63,976 | 0 | 2,573,404 | 0.00 | 79,609 | <11 | 3,077,909 | 0.78 |
| 16-17 | 57,831 | <11 | 2,319,748 | 1.77 | 43,124 | <11 | 1,735,642 | 3.82 | 50,607 | <11 | 1,954,338 | 0.48 |
| Non-hemorrhagic stroke | Primary Series | 5-11 | 603,620 | 0 | 14,973,614 | 0.00 | 605,190 | <11 | 15,182,777 | 2.44 | 572,772 | 0 | 14,156,125 | 0.00 |
| 12-15 | 573,510 | 0 | 14,304,561 | 0.00 | 653,814 | 0 | 16,468,867 | 0.00 | 566,004 | 0 | 14,069,866 | 0.00 |
| 16-17 | 291,775 | <11 | 7,298,163 | 1.65 | 335,217 | 0 | 8,502,438 | 0.00 | 286,197 | <11 | 7,151,916 | 0.99 |
| Dose 1 | 5-11 | 318,565 | 0 | 7,238,863 | 0.00 | 335,611 | <11 | 7,844,822 | 4.61 | 310,691 | 0 | 7,096,122 | 0.00 |
| 12-15 | 302,226 | 0 | 6,798,090 | 0.00 | 356,878 | 0 | 8,227,890 | 0.00 | 302,701 | 0 | 6,848,826 | 0.00 |
| 16-17 | 155,470 | <11 | 3,524,039 | 3.42 | 187,253 | 0 | 4,394,094 | 0.00 | 155,873 | 0 | 3,578,081 | 0.00 |
| Dose 2 | 5-11 | 285,055 | 0 | 7,734,751 | 0.00 | 269,579 | 0 | 7,337,955 | 0.00 | 262,081 | 0 | 7,060,003 | 0.00 |
| 12-15 | 271,284 | 0 | 7,506,471 | 0.00 | 296,936 | 0 | 8,240,977 | 0.00 | 263,303 | 0 | 7,221,040 | 0.00 |
| 16-17 | 136,305 | 0 | 3,774,124 | 0.00 | 147,964 | 0 | 4,108,344 | 0.00 | 130,324 | <11 | 3,573,835 | 1.98 |
| Dose 3 | 5-11 | 11,446 | 0 | 87,634 | 0.00 | 1,341 | 0 | 33,429 | 0.00 | 19,048 | 0 | 291,412 | 0.00 |
| 12-15 | 86,169 | 0 | 2,248,357 | 0.00 | 63,983 | 0 | 1,697,487 | 0.00 | 79,623 | 0 | 2,092,148 | 0.00 |
| 16-17 | 57,855 | <11 | 1,536,784 | 8.80 | 43,144 | <11 | 1,152,674 | 21.01 | 50,632 | 0 | 1,327,126 | 0.00 |
| Pulmonary embolism (PE) | Primary Series | 5-11 | 603,628 | 0 | 15,109,619 | 0.00 | 605,187 | 0 | 15,312,029 | 0.00 | 572,776 | 0 | 14,156,230 | 0.00 |
| 12-15 | 573,504 | <11 | 14,338,531 | 1.06 | 653,808 | 0 | 16,512,834 | 0.00 | 566,002 | <11 | 14,069,828 | 0.56 |
| 16-17 | 291,724 | <11 | 7,314,350 | 1.58 | 335,190 | <11 | 8,524,694 | 1.79 | 286,159 | 0 | 7,150,951 | 0.00 |
| Dose 1 | 5-11 | 318,569 | 0 | 7,303,427 | 0.00 | 335,608 | 0 | 7,897,662 | 0.00 | 310,694 | 0 | 7,096,199 | 0.00 |
| 12-15 | 302,224 | 0 | 6,816,484 | 0.00 | 356,874 | 0 | 8,252,689 | 0.00 | 302,699 | 0 | 6,848,786 | 0.00 |
| 16-17 | 155,442 | <11 | 3,533,778 | 2.18 | 187,238 | <11 | 4,407,873 | 2.61 | 155,851 | 0 | 3,577,578 | 0.00 |
| Dose 2 | 5-11 | 285,059 | 0 | 7,806,192 | 0.00 | 269,579 | 0 | 7,414,367 | 0.00 | 262,082 | 0 | 7,060,031 | 0.00 |
| 12-15 | 271,280 | <11 | 7,522,047 | 2.02 | 296,934 | 0 | 8,260,145 | 0.00 | 263,303 | <11 | 7,221,042 | 1.10 |
| 16-17 | 136,282 | <11 | 3,780,572 | 1.02 | 147,952 | <11 | 4,116,821 | 0.93 | 130,308 | 0 | 3,573,373 | 0.00 |
| Dose 3 | 5-11 | 11,446 | 0 | 113,843 | 0.00 | 1,341 | 0 | 34,377 | 0.00 | 19,048 | 0 | 291,412 | 0.00 |
| 12-15 | 86,168 | 0 | 2,319,678 | 0.00 | 63,983 | 0 | 1,746,941 | 0.00 | 79,622 | 0 | 2,092,120 | 0.00 |
| 16-17 | 57,847 | <11 | 1,563,040 | 2.60 | 43,141 | 0 | 1,173,213 | 0.00 | 50,627 | 0 | 1,326,986 | 0.00 |
| Seizures/convulsions | Primary Series | 5-11 | 732,503 | 15 | 5,804,883 | 1.81 | 721,478 | 24 | 5,748,418 | 1.79 | 676,710 | 12 | 5,356,934 | 1.33 |
| 12-15 | 685,589 | 17 | 5,467,492 | 1.60 | 768,292 | 20 | 6,136,727 | 1.11 | 666,728 | 13 | 5,310,571 | 1.16 |
| 16-17 | 347,431 | 11 | 2,770,390 | 1.63 | 391,217 | 17 | 3,123,757 | 1.27 | 335,928 | <11 | 2,675,382 | 0.91 |
| Dose 1 | 5-11 | 388,213 | <11 | 3,076,139 | 2.26 | 401,399 | <11 | 3,199,876 | 1.98 | 369,270 | <11 | 2,922,238 | 1.22 |
| 12-15 | 363,843 | <11 | 2,900,710 | 1.42 | 422,576 | <11 | 3,375,193 | 0.91 | 358,999 | <11 | 2,859,080 | 1.33 |
| 16-17 | 186,243 | <11 | 1,484,375 | 2.22 | 220,499 | <11 | 1,760,130 | 1.33 | 184,243 | <11 | 1,467,105 | 1.04 |
| Dose 2 | 5-11 | 344,290 | <11 | 2,728,744 | 1.29 | 320,079 | <11 | 2,548,542 | 1.53 | 307,440 | <11 | 2,434,696 | 1.46 |
| 12-15 | 321,746 | <11 | 2,566,782 | 1.81 | 345,716 | <11 | 2,761,534 | 1.36 | 307,729 | <11 | 2,451,491 | 0.97 |
| 16-17 | 161,188 | <11 | 1,286,015 | 1.28 | 170,718 | <11 | 1,363,627 | 1.20 | 151,685 | <11 | 1,208,277 | 0.76 |
| Dose 3 | 5-11 | 13,572 | 0 | 34,157 | 0.00 | 1,476 | 0 | 11,690 | 0.00 | 21,413 | 0 | 141,013 | 0.00 |
| 12-15 | 96,123 | <11 | 747,307 | 3.04 | 66,287 | <11 | 527,774 | 0.73 | 85,908 | <11 | 672,632 | 1.44 |
| 16-17 | 65,777 | <11 | 516,066 | 0.86 | 45,550 | 0 | 361,811 | 0.00 | 55,387 | 0 | 434,725 | 0.00 |

Abbreviation: RR, rate ratio; IP, inpatient; OP-ED, Outpatient Emergency Department

*Data cuts: CVS Health data through 5/31/2022, HealthCore data through 5/6/2022, and Optum data through 6/25/2022*

\*indicates the AESI has signaled in the data.

Cell sizes 1-10 were masked for confidentiality

**Supplemental Table 5. Descriptive Outcome Counts, Overall and by Data Partners**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Outcome** | **All Data Partners** | **CVS (data through 5/31/22)** | **HealthCore (data through 5/6/22)** | **Optum (data through 6/25/22)** |
| **# of Vaccine Doses** | **# of Vaccine Doses** | **# of Vaccine Doses** | **# of Vaccine Doses** | **# of Vaccine Doses** | **# of Outcomes** | **# of Vaccine Doses** | **# of Outcomes** |
| **AMI** | 4,904,152 | 1,625,585 | 1,703,210 | 1,575,357 | 1,575,357 | <11 | 1,575,357 | 0 |
| **GBS** | 4,904,135 | 1,625,574 | 1,703,207 | 1,575,354 | 1,575,354 | <11 | 1,575,354 | <11 |
| **Hemorrhagic Stroke** | 4,904,039 | 1,625,548 | 1,703,163 | 1,575,328 | 1,575,328 | <11 | 1,575,328 | <11 |
| **Kawasaki Disease** | 4,903,075 | 1,625,217 | 1,702,843 | 1,575,015 | 1,575,015 | 19 | 1,575,015 | 24 |
| **MIS-C** | 4,903,902 | 1,625,518 | 1,703,107 | 1,575,277 | 1,575,277 | <11 | 1,575,277 | <11 |
| **Transverse Myelitis** | 4,904,143 | 1,625,584 | 1,703,206 | 1,575,353 | 1,575,353 | 0 | 1,575,353 | <11 |
| **Unusual Site Thromboses** | 4,904,140 | 1,625,582 | 1,703,209 | 1,575,349 | 1,575,349 | 0 | 1,575,349 | 0 |

Cell sizes 1-10 were masked for confidentiality

### References

1. Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022; 327(4):331–340. doi:10.1001/jama.2021.24110
2. Klein N. Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and “Head-to-Head” Product Comparisons. Presented on: October 21, 2021. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/08-COVID-Klein-508.pdf>.
3. Dodd, C.N., et al., International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013; 31(40): p. 4448-4458.
4. Schonberger, L.B., et al., Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. American Journal of Epidemiology. 1979; 110(2): p. 105-123.
5. Hennon, T.R., et al., COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Progress in Pediatric Cardiology. 2020;
6. Pellegrino, P., et al., Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. PloS one. 2013; 8(10): p. e77766.
7. Agmon-Levin, N., et al., Transverse myelitis and vaccines: a multi-analysis. Lupus. 2009; 18(13): p. 1198-1204.
8. Rüggeberg, J.U., et al., Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007; 25(31): p. 5675-5684.
9. Su, J.R., et al., Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. Journal of Allergy and Clinical Immunology. 2019; 143(4): p. 1465-1473.
10. Pishko, A.M., et al., COVID-19 vaccination and immune thrombocytopenia. Nat Med 27. 1145–1146 (2021).
11. Whitworth, H., et al., Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 138(2), 190-198.
12. Duffy, J., et al., Febrile seizure risk after vaccination in children 6 to 23 months. Pediatrics. 2016; 138(1).
13. Renoud L; et al; Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern Med. 2021; 181(9):1243–1245.
14. Kearon, C., Natural history of venous thromboembolism. Circulation. 2003; 107(23\_suppl\_1): p. I-22-I-30.
15. Kearon, C. and E.A. Akl, Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014; 123(12): p. 1794-1801.
16. Vickers, E.R., et al., Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink. Vaccine. 2017; 35(43): p. 5872-5877.
17. Tang, N., et al., Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis Haemostasis. 2020; 18(4): p. 844-847.
18. Black, C., J.A. Kaye, and H. Jick, MMR vaccine and idiopathic thrombocytopaenic purpura. British Journal of Clinical Pharmacology. 2003; 55(1): p. 107-111.
19. D'alò, G.L., et al., Frequently asked questions on seven rare adverse events following immunization. Journal of Preventive Medicine Hygiene. 2017; 58(1): p. E13.
20. Baker, M.A., et al., Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PLOS Medicine. 2019; 16(7): p. e1002844.
21. Yung, C.F., et al., Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children. Scientific reports. 2019; 9(1): p. 1-7.
22. Duffy, J., et al., Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United States. Neurology. 2014; 83(20): p. 1823-1830.
23. Montplaisir, J., et al., Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PloS one. 2014; 9(9): p. e108489.
24. Sarkanen, T.O., et al., Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep Medicine Reviews. 2018; 38: p. 177-186.
25. Donahue, J.G., et al., Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019; 144(6): p. e20191808.
26. Gee, J., et al., Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011; 29(46): p. 8279-84.
27. Al Qudah, Z., W. Abukwaik, and N. Souayah, Stroke after Vaccination in United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. [1990–2010] (P01.009). Neurology. 2012; 78(1 Supplement): p. P01.009-P01.009.
28. Smeeth, L., et al., Risk of myocardial infarction and stroke after acute infection or vaccination. New England Journal of Medicine. 2004; 351(25): p. 2611-2618.
29. Center for Biologics Evaluation and Research, BEST Initiative (2022, April 12). *CBER Surveillance Program Biologics Effectiveness and Safety Initiative,* Retrieved from <https://bestinitiative.org/wp-content/uploads/2022/04/C19-Active-Monitoring-Protocol-Addendum-2022.pdf>.
30. Center for Biologics Evaluation and Research, BEST Initiative (February 10, 2021). *CBER Surveillance Program Biologics Effectiveness and Safety Initiative,* Retrieved from <https://bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-Protocol-2021.pdf>